AstraZeneca eyes KESTREL as EAGLE flops
There was no good news from the results of AstraZeneca’s (LSE: AZN) Phase III EAGLE trial, although the fact that the failure did not seem that important was good news in itself.
Shares were undamaged by Friday’s announcement of the overall survival (OS) results, which showed that Imfinzi (durvalumab) as a monotherapy or with tremelimumab did not improve OS compared to standard-of-care chemotherapy recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) patients who experienced disease progression following platinum-based chemotherapy, regardless of PD-L1 tumor status.
Sean Bohen, executive vice president, global medicines development and chief medical officer, said: “The prognosis for recurrent or metastatic HNSCC is very poor and new treatments for this group of cancers are urgently needed.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze